Skip Navigation

European Heart Journal 2004 25(15):1369; doi:10.1016/j.ehj.2004.04.037
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nicol, P.
Right arrow Articles by Axelson, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicol, P.
Right arrow Articles by Axelson, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Contrast agent nephropathy

Peter Nicol and Christian Axelson

Department of Medicine, Köping Hospital, Glasgatan 4, 731 81 Köping, SwedenTel.: +46-221-26000; Fax: +46-221-26515

E-mail address: peter.nicol{at}ltvastmanland.se

Dear Sir

The meta-analysis in the Lancet 23 August 20031 concluded that acetylcysteine significantly reduces the risk of contrast nephropathy in patients with chronic renal insufficiency, and that the relative risk of contrast nephropathy was not related to the amount of radio contrast media given. Yet, as we see from a recent issue of the European Heart Journal, doubt seems to remain concerning both questions2–4. Is it not time to do a large multi-centre trial?

References

  1. Birck R, Krzossok S, Markowetz F et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362(9384):598–603.[CrossRef][Web of Science][Medline]
  2. Briguori C, Colombo A, Violante A et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur. Heart J. 2004;25(3):206–211.[Abstract/Free Full Text]
  3. Goldenberg I, Shechter M, Matetzky S et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur. Heart J. 2004;25(3):212–218.[Abstract/Free Full Text]
  4. Billinger M, Hess OM, Meier B. Prevention of contrast-induced renal dysfunction by N-acetylcysteine. Truth or myth? Eur. Heart J. 2004;25(3):188–189.[Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nicol, P.
Right arrow Articles by Axelson, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicol, P.
Right arrow Articles by Axelson, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?